Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

42°
- Benton, AR (72018)
  Today
  
  Sunshine and clouds mixed. Expect mist and reduced visibilities at times. High 71F. Winds light and variable..
  
  Tonight
  
  Partly cloudy skies early will give way to cloudy skies late. Areas of patchy fog. Low 53F. Winds light and variable.
  
  Updated: January 7, 2026 @ 8:14 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

43.96 +0.99 (+2.30%)

Streaming Delayed Price Updated: 9:41 AM EST, Jan 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗

January 05, 2026

There is a key difference between these two biotechs.

Via The Motley Fool

Topics Bankruptcy

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗

December 28, 2025

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

Via The Motley Fool

Topics Regulatory Compliance

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗

December 28, 2025

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Via The Motley Fool

Topics Regulatory Compliance

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Shares in the biotech company have surged on news of a big pharma takeover.

Via The Motley Fool

Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher ↗

November 06, 2025

Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading.

Via Chartmill

This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street ↗

October 13, 2025

Is it too late to get on the bandwagon?

Via The Motley Fool

Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September ↗

October 05, 2025

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

October 03, 2025

Via Benzinga

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? ↗

September 21, 2025

Here's what needs to happen for these high flyers to continue soaring.

Via The Motley Fool

Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today ↗

September 18, 2025

One of the company's pipeline drugs is showing significant promise.

Via The Motley Fool

Why Is Nektar Therapeutics Stock Trading Lower On Thursday? ↗

September 18, 2025

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

Via Benzinga

Why Nektar Therapeutics Rippled Higher This Week ↗

September 05, 2025

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Via The Motley Fool

Topics Intellectual Property

What's Going On With Nektar Therapeutics Stock On Thursday? ↗

September 04, 2025

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 04, 2025

Via Benzinga

Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday ↗

September 04, 2025

Via Benzinga

Why Nektar Therapeutics Stock Popped 6% on Friday ↗

August 08, 2025

The company said it has sufficient financial resources to fund its operations into early 2027.

Via The Motley Fool

Nektar (NKTR) Q2 Revenue Falls 52% ↗

August 08, 2025

Via The Motley Fool

3 Bullish Biotech Stocks With Explosive Growth Trends ↗

July 21, 2025

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

Via MarketBeat

Why Nektar Therapeutics Stock Dived by 3% Today ↗

July 03, 2025

Via The Motley Fool

US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%...,' Says Expert ↗

July 01, 2025

U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower.

Via Benzinga

MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday ↗

July 01, 2025

Via Benzinga

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains ↗

June 30, 2025

With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?

Via MarketBeat

Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

June 28, 2025

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

Via MarketBeat

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside ↗

June 25, 2025

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis.

Via Stocktwits

Why Nektar Therapeutics Stock Was Red-Hot Today ↗

June 25, 2025

Via The Motley Fool

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday? ↗

June 25, 2025

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Nektar Therapeutics - Common Stock (NQ:NKTR)

All News about Nektar Therapeutics - Common Stock

Sections

Services

Follow Us